Androgen Deprivation Therapy News and Research

RSS
GTx reports revenue of $1.6 million for second quarter 2012

GTx reports revenue of $1.6 million for second quarter 2012

Calcium and vitamin D supplements do not prevent bone loss in men with prostate cancer

Calcium and vitamin D supplements do not prevent bone loss in men with prostate cancer

Older men with higher levels of free testosterone more likely to develop prostate cancer

Older men with higher levels of free testosterone more likely to develop prostate cancer

Debiopharm initiates Debio 8206 Phase III study on advanced prostate cancer

Debiopharm initiates Debio 8206 Phase III study on advanced prostate cancer

Prostate cancer treatment regrets linked to comorbidity

Prostate cancer treatment regrets linked to comorbidity

Split-course RT valuable after hormone-resistant prostate cancer relapse

Split-course RT valuable after hormone-resistant prostate cancer relapse

Many men with metastatic prostate cancer live longer on continuous hormone therapy

Many men with metastatic prostate cancer live longer on continuous hormone therapy

Additional data from Tokai’s galeterone Phase 1 study on CRPC

Additional data from Tokai’s galeterone Phase 1 study on CRPC

Galeterone safe, effective for patients with CRPC

Galeterone safe, effective for patients with CRPC

GTx fourth quarter net loss increases to $10.7 million

GTx fourth quarter net loss increases to $10.7 million

Curcumin may block growth of castrate-resistant prostate tumors

Curcumin may block growth of castrate-resistant prostate tumors

Cabazitaxel with IMRT, androgen deprivation therapy may extend survival for prostate cancer patients

Cabazitaxel with IMRT, androgen deprivation therapy may extend survival for prostate cancer patients

Hormone-blocking therapy for prostate cancer does not raise risk of heart attacks

Hormone-blocking therapy for prostate cancer does not raise risk of heart attacks

GTx third quarter net loss increases to $9.3 million

GTx third quarter net loss increases to $9.3 million

Benefits of combined therapy for men with high-risk prostate cancer

Benefits of combined therapy for men with high-risk prostate cancer

UCLA's gene-based imaging system can accurately detect metastatic prostate cancers

UCLA's gene-based imaging system can accurately detect metastatic prostate cancers

Adamis receives patents for APC-200 prostate cancer drug in South Africa, Singapore

Adamis receives patents for APC-200 prostate cancer drug in South Africa, Singapore

Amgen's Prolia receives FDA approval for new indications to treat cancer patients

Amgen's Prolia receives FDA approval for new indications to treat cancer patients

GTx reports revenue of $1.6 million for second quarter 2011

GTx reports revenue of $1.6 million for second quarter 2011

Hormone therapy may be hazardous in men with pre-existing heart conditions

Hormone therapy may be hazardous in men with pre-existing heart conditions